Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976913 | 1.00 | THRB (0.40) | THRBALOX15SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL12087571 | 1.00 | THRB (0.40) | THRBALOX15SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL11300063 | 0.83 | SMN1; SMN2 (0.35) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL13637440 | 0.83 | SMN1; SMN2 (0.35) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL11299412 | 0.83 | SMN1; SMN2 (0.35) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL10305203 | 0.81 | THRB (0.36) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL16976910 | 0.79 | RAB9A (0.37) | THRBALOX15SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL13627273 | 0.79 | RAB9A (0.37) | THRBALOX15SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL12087568 | 0.79 | RAB9A (0.37) | THRBALOX15SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL8412576 | 0.76 | THRB (0.32) | THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090287003-A1 | Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost | EASTAR CHEMICAL, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090287003-A1 | Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost | EASTAR CHEMICAL, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090287003-A1 | Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost | PTGIS, PTGES, PTGES2 | THRB 2630/4885ALOX15 39/4885SMN1; SMN2 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.